Request under Freedom of Information Act 2000

Request Ref: NGFOI 17/18: 442

Thank you for your request for information received at Northampton General Hospital NHS Trust (NGH) on 03/01/18.

I am pleased to be able to provide you with the following information.

1. *Do you test newly diagnosed bowel cancer patients in your trust (either contracted or referred) for molecular features of Lynch syndrome using either immunohistochemistry or microsatellite instability testing?*

   - ✓ ***Yes – all bowel cancer patients, as per DG 27 NICE guidance***
   - *Yes - everyone under the age of 70*
   - *Yes – everyone under the age of 50*
   - *Yes – according to family history of the disease*
   - *No*
   - *Other*

2. *If yes, at what stage does this testing take place?*

   - *Pre-treatment i.e. at diagnosis (on a biopsy of the tumour)*
   - ✓ ***Post treatment i.e. test is carried out on the tumour resection specimen only.***
   - *Not applicable*

3. *Is this test carried out as a reflex test i.e. automatically or upon referral?*

   - ✓ ***Reflex***
   - *Referral via MDT*
   - *Referral via Genetics Centre*
   - *Referral via GP*
   - *Other (please explain)*
   - *Not applicable*

4. *In their published adoption support resource NICE suggest identifying a named 'clinical champion' within each colorectal multidisciplinary team to effectively implement testing people for molecular features for Lynch syndrome. Is this established in your trust?*

   - *Yes, Gastroenterologist*
   - *Yes, Colorectal Surgeon*

- *Yes, Oncologist*
- *Yes, Clinical Geneticist*
- *Other (please explain)*
- ✓ ***No***

5. *Do you audit diagnostic outcomes within your trust to ensure that every patient is tested for molecular features for Lynch syndrome?*

- *Yes, as part of private audit*
- *Yes, and the data is publicly released*
- ✓ ***No***

6. *Have you had to submit a business case for funding in order to effectively implement this new guidance?*

- *Yes, and additional funding was provided fully/partially as requested. Please provide information.*
- *Yes, but no additional funding was provided. Please provide information on why.*
- ✓ ***No please provide information on why. No business case relating to this has been submitted to date.***

7. *If no such testing is in place, do you have information on whether there are any plans to introduce molecular testing for Lynch syndrome as per NICE guidance?*
Not known at present.

8. *What are the main barriers you have faced if no molecular testing or only selected testing is performed? Please specify.*

- *Financial*
- *Policy*
- *Awareness of current guidance*
- *Staff resources*
- ✓ ***Other (please specify); No centrally held records relate to this issue.***